Background: A pediatric vaccine to prevent breast milk transmission of human im-
| INTRODUC TI ON
Breast-feeding is critical for providing nutrition and passive immunity to infants in resource-poor countries, but it poses a considerable risk for postpartum mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV). [1] [2] [3] While maternal access to antiretroviral therapy in resource-poor areas is increasing, only 60% of pregnant HIV-positive women receive it. 4, 5 Pediatric HIV infection remains an important issue in developing countries, with an estimated 150 000 new cases in 2015, approximately half from breast-feeding, in addition to 110 000 AIDS-related pediatric deaths. 6 Thus, additional means to prevent MTCT of HIV, such as vaccination, are urgently needed.
We previously showed that intramuscular (IM) poxvirus- viremia. 8 Topical administration of live attenuated SIV∆nef to the palatine and lingual tonsils (T) provided protection against tonsillar or rectal challenge with SIVmac251. [9] [10] [11] There is more limited information regarding the sublingual (SL) vaccine delivery route in macaques. But in one study, SL immunization of juvenile macaques with live attenuated vaccinia viruses expressing HIV envelope (Env) protein was shown to elicit Env-specific systemic IgG responses, although no mucosal IgA responses were detected.
12
DNA prime/poxviral vector boost vaccine strategies have been studied extensively in adult rhesus macaques using SIV infection models. 13 Adult rhesus macaques vaccinated two times by the IM route with DNA encoding SIV viruslike particles and granulocytemacrophage colony-stimulating factor (GM-CSF) 14 or CD40 ligand (CD40L) 15 adjuvants and boosted with MVA encoding SIV gag,pol,env (SIV-MVA) have been protected against rectal challenge with heterologous SIV. 14, 15 Additionally, a recent HIV vaccine efficacy trial with human adults in Thailand utilized a canarypox virus prime, which elicited immune responses capable of reducing infection by 31%.
16
In this proof-of-concept study, we tested the immunogenicity of the oral, T, and SL delivery routes using SIV-expressing DNA and MVA in juvenile macaques. Juvenile macaques were chosen because their larger size enabled us to test the feasibility of applying small vaccine volumes to specific oral mucosal sites prior to testing this approach in infant macaques. The results suggest that delivery of vaccine using a combination of oral and IM routes may be superior to oral or IM vaccination routes alone for generating both mucosal and systemic immune responses.
| MATERIAL S AND ME THODS

| Humane care guidelines
Simian immunodeficiency virus and type D retrovirus-negative juvenile rhesus macaques (Macaca mulatta) were housed in pairs at the 
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| Vaccines and study design
The vaccination schedule is outlined in Table 1 
| Sample processing
Plasma was harvested from EDTA anticoagulated whole blood via centrifugation and stored at −80°C. Mononuclear cells (MNCs)
were isolated as described. 19, 20 Saliva and stool were collected, stored, and processed as described. 21, 22 Lymph nodes (LNs; submandibular, retropharyngeal, submental, and mesenteric), spleen, tonsil, ileum, and colon were collected at euthanasia and processed as previously described. 3, 19 MNCs were used fresh or stored in liquid nitrogen.
| Antibody quantification in plasma, saliva, and stool
Simian immunodeficiency virus-specific and total antibodies in plasma, saliva, and fecal extracts prepared from stool (reflective of intestinal antibodies) were assessed by ELISA as described. at a 1/400 coating dilution that lacked detectable Env protein.
Concentrations of SIV Env or Gag,Pol-specific IgA in secretions were normalized to the total IgA concentration by calculating the specific activity (sp act; ng-specific IgA per μg total IgA). Samples were considered antibody positive if the sp act was ≥the mean sp act + 3 SD in naïve (pre-immunization) secretions. 
| ELISPOT for antibody-secreting cells
| T-cell subset analysis
Frozen cells were thawed, washed and cultured in cRPMI ( Brefeldin A (eBiosciences) was added after 1 hour. Cells were stained with viability dye (Invitrogen) and anti-CD3, -CD4, -CD8, -CD45RA, and -CCR7 antibodies, treated with Cytofix/Cytoperm, and stained with anti-TNF-α, -IFN-γ, -IL-2, and -IL-17 antibodies (all from BD). Data collection and analysis were performed as above. SIV Gag-specific cytokine responses were normalized to unstimulated controls.
| SIV-specific T-cell responses
| Statistical analyses
Due to small group sizes, comparisons were performed using the nonparametric two-tailed Mann-Whitney rank-sum test and GraphPad Prism v6.0 software (La Jolla, CA). P values ≤0.05 were considered significant.
| RE SULTS
| SIV-specific antibody responses
We quantified SIV gp140 Env-specific antibodies in plasma 3 weeks after the first and second vaccine boosts with SIV-MVA (weeks 6 and 9). No differences were observed in animals primed with adjuvanted vs non-adjuvanted DNA, possibly because only a single priming immunization with these adjuvants was performed.
The O/T and O/SL immunizations failed to induce Env-specific IgG or IgA in plasma ( Figures 1A-D) . The IM/IM and O+IM/SL vaccinees had Env-specific plasma IgG after the first boost, and the second boost increased concentrations to levels that were roughly 1000-fold above pre-immune ( Figure 1A ,B). Env-specific F I G U R E 1 Systemic and mucosal antibody responses. SIV gp140 Envspecific IgG-binding antibodies in plasma were measured on week 6 (A) and week 9 (B) after immunization using ELISA. C, The avidity index of anti-gp140 plasma IgG in vaccine groups found to have these antibodies. D, SIV gp140-specific plasma IgA antibodies on week 9. E and F, IgA-specific activity (ng IgA antibody per μg of total IgA) measured in saliva to SIV gp140 Env and SIV Gag,Pol, respectively, on week 9. G and H, IgA-specific activity measured in fecal extracts to Env and Gag,Pol, respectively, on week 9. 
| Tissue SIV-specific B cells and Induction of follicular T helper (T FH ) cells
We used ELISPOT to measure Env-specific ASC in oral LNs (retropharyngeal, submental, or submandibular) and spleen collected Figure 3E ).
In contrast, macaques in the O/SL group had higher T REG frequencies compared to other groups ( Figure 3H ). Figure 3I ). In the spleen, few IL-4-or IL-21-producing T FH were found ( Figure 3J ).
| SIV Gag-specific tissue T-cell responses
We also tested whether SIV-specific CD4 + and CD8 + T-cell responses were induced in tonsils, LNs draining the oral cavity, and intestinal tissues on week 9 ( Figure 4 , Table 2 ). Only four animals in the O/T group had sufficient cell numbers to test Gag-specific T-cell responses in tonsils, and only 1 had detectable Gag-specific T cells. In contrast, Gag-specific T cells were found in tonsils of 67%, 100%, and 80% of the animals vaccinated by the O/SL, IM/ IM, or O+IM/SL routes, respectively ( Figure 4 , Table 2 ). However, 
responses in oral and mesenteric LNs ( Figure 4 , Table 2 ). The most Gag-specific T-cell responses were induced in animals both primed by the O+IM routes and boosted by the SL route ( Figure 4 , Table 2 ). The 
| D ISCUSS I ON
A pediatric vaccine to prevent breast milk transmission of HIV likely needs to induce both orogastrointestinal and systemic immune responses. This proof-of-concept study investigated whether an oral-only DNA-SIV prime/MVA-SIV boost strategy, administered at specific sites in the oral cavity, could induce oral, gastrointestinal, and systemic SIV-specific immune responses.
In previous infant macaque studies, we have found that vaccineinduced SIV-specific plasma IgG and mucosal IgA antibodies at the time of oral SIV challenge were associated with reduced viremia. 19, 34 In contrast to these former studies that utilized peroral ( However, it is possible that there was insufficient MVA contact time and/or drainage from the tonsil into the oral cavity. Although the amount of vaccine directly taken up by the oral mucosa vs intestinal tissue cannot be quantified, SL vaccine delivery resulted in more consistent T-cell and intestinal IgA responses when compared to tonsillar delivery.
Sublingual vaccines to protect against infectious diseases have proved successful in mouse models, [40] [41] [42] [43] and the first immunogenicity studies of a SL papillomavirus vaccine have been conducted in humans. 44 Although poor neutralizing antibody responses were observed in the latter human study, this could be attributed to the delivery of a suboptimal amount of vaccine and adjuvant. 43, 44 Novel vaccine delivery modes (eg films), smaller vaccine volumes, and mucosal adjuvants should be tested in future studies to enhance SL vaccine-induced immune responses. The adjuvants used in the current study were selected for their ability to enhance dendritic cell priming and increase mucosal IgA responses in adult macaques given two IM immunizations with adjuvanted DNA. 14, 15 The lack of observed benefits of GM-CSF or CD40L DNA adjuvants in this study could be due to our having per- 
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